Table 1 Demographic and clinical data.
From: Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients
PD ICB− | PD ICB+ | p-value | |
|---|---|---|---|
N | 14 | 19 | |
Sex (M/F) | 9/5 | 10/9 | 0.754 |
Age (years) | 67.2 ± 7.4 | 61.6 ± 6.5 | 0.039 |
Disease duration (years) | 7.2 ± 4.2 | 4.3 ± 3.3 | 0.021 |
Movement Disorders Society-United Parkinson Disease Rating Scale (MDS-UPDRS) | |||
Part II | 18.1 ± 10.3 | 18.9 ± 11.0 | 0.867 |
Part III (Off) | 30.7 ± 10.6 | 29.5 ± 14.2 | 0.572 |
Part III (On) | 27.8 ± 10.6 | 20.0 ± 9.9 | 0.031 |
Questionnaire for impulsive Compulsive Disorders in Parkinson’s disease Rating Scale (QUIP-RS) | 17.4 ± 9.3 | 29.1 ± 13.3 | 0.008 |
Montreal Cognitive Assessment (MoCA) | 25.8 ± 2.3 | 27.0 ± 2.1 | 0.07 |
Center for Epidemiologic Studies Depression Scale (CESD-R) | 12.2 ± 6.4 | 17.1 ± 10.0 | 0.08 |
Dopamine replacement therapy | |||
Total levodopa daily dose (LEDD) (mg/day) | 792.2 ± 436.1 | 642.7 ± 366.9 | 0.414 |
Dopamine agonist single dose equivalent (mg/day) | 102.0 ± 109.0 | 118.0 ± 64.0 | 0.126 |
